Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The FKBP1A – RyR2 complex is a critical regulatory assembly in cardiac myocytes that governs the release of calcium from the sarcoplasmic reticulum. FKBP1A (also known as FKBP12 or Calstabin1) acts as a stabilizing subunit that binds to the Ryanodine receptor 2 (RyR2), the primary calcium release channel in the heart. This interaction is essential for maintaining the channel in a closed state during the resting phase (diastole) of the cardiac cycle, ensuring that calcium is only released during contraction (systole). In pathological states such as chronic heart failure or genetic arrhythmias like CPVT, the complex becomes destabilized—often due to hyperphosphorylation of RyR2 or oxidative stress—leading to 'leaky' channels that cause triggered arrhythmias and contractile dysfunction. Therapeutic agents known as 'Rycals' are designed to re-stabilize this complex, preventing the dissociation of FKBP from RyR2 and thereby reducing pathological calcium leaks. While FKBP1B (FKBP12.6) is often cited as the primary cardiac isoform, FKBP1A is also a significant component of the RyR2 macromolecular complex and a target for pharmacological stabilization.
Stabilization of the binding between FKBP1A (or its isoform FKBP1B) and the RyR2 channel to prevent pathological diastolic calcium leakage; inhibition of RyR2 dissociation caused by PKA hyperphosphorylation or oxidative stress.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on FK506-binding protein 1A – Ryanodine receptor 2 complex (FKBP12–RyR2 complex).